How are you approaching patients with Stage IV EGFR NSCLC who progress on first line TKI and are found to have retained EGFR mutation as well as MET amplification?

Topics: Thoracic Malignancies • Medical Oncology

Answer from: Medical Oncologist at Academic Institution

The nuance is here is how the MET amplification was detected and defined. Was it through an NGS platform (such as Guardant) or through FISH based testing? If the latter, what was the MET gene copy number, and what was the ratio of MET/CEP7?Nonetheless, assuming MET amplification is an accurate bypas...

Comments

Medical Oncologist at Onc San Antonio
Thank you Dr. @Tejas Patil for your insight, ...

Medical Oncologist at University of Colorado
I would get FISH based testing unless your NGS ass...

Medical Oncologist at New York Methodist Hosp
I have seen responses with increasing osimertinib ...

Medical Oncologist at Onc San Antonio
Thank you for your valuable input.

Related Questions